PubMed Health⌕ Search

Biomedical subjects

D Lavanchy

Publications and source records attributed to D Lavanchy.

44 records · Page 3Linked to original sources

Monoclonal antibodies to the multienzyme enniatin synthetase. Production and use in structural studies.

Monoclonal antibodies have been prepared against the multifunctional enzyme enniatin synthetase, which catalyses the biosynthesis of the cyclodepsipeptide antibiotic enniatin. Five different antibodies (designated 1.56, 21.1, 25.91, 28.7 and 28.34) were characterized. 1.56, 21.1 and 25.91 were of IgG1 and 28.7 and 28.34 of IgM subclass. Binding studies showed that 21.1 and 25.91 are obviously directed against determinants based on the primary structure of the enzyme, whereas 28.7, 28.34 and 1.56 bind to the native enzyme. All antibodies inhibited enniatin formation. Based on their ability to inhibit different partial reactions of the multienzyme the antibodies could be divided into three groups: 21.1 and 25.91 inhibit valyl thioester formation, 1.56 additionally inhibits D-2-hydroxyisovaleric acid thioesterification, and 28.7 and 28.34 block both thioester sites as well as the N-methylation step. None of the antibodies affected the formation of L-valyl or D-hydroxyisovaleryl adenylate by the enzyme. The results indicate that there must be distinct thioester activation sites for valine and D-hydroxyisovalerate close to each other and in the neighbourhood of the methyltransferase site. The adenylation sites for D-hydroxy-isovalerate and L-valine are obviously located at some distance.

Affinity Labels↗

[Lymphocyte stimulation in various age groups].

The study of lymphocyte functions is of great significance for evaluation of the immune response. One of the most valuable assays being the mitogenic response of lymphocytes to different antigens or mitogens, the question of the extent to which lymphocyte response decreased with advancing age has been studied. Peripheral blood lymphocytes from healthy individuals aged 21 to 97 years were assayed for the blastogenic response to different mitogens. A significant age-dependent reduction of lymphocyte stimulation could be observed with two of the three mitogens tested. Since these mitogens in the concentrations used are mainly T lymphocyte stimulators, it can be concluded that an age-dependent reduction in T lymphocyte functions is present. These findings are not only of diagnostic significance but also have therapeutic implications for all geriatric diseases in which immunity may play a role. Furthermore, the experiments described show that the lymphocyte transformation assay with different mitogens is a simple reproducible assay which has its place in every routine evaluation of the immune response system.

Adult↗

Planning for the next pandemic of influenza.

Worldwide influenza pandemics have occurred at irregular and unpredictable intervals throughout history and it is confidently expected that they will continue to occur in the future. It is now recognised that these pandemics result when avian influenza A viruses succeed in adaptation to and transmission between humans. The impact of pandemic influenza is substantial in terms of morbidity, mortality and economic cost and there is the potential for serious social disruption. Influenza vaccines remain the most effective defence against influenza but will be in short supply during a pandemic, as will the new specific anti-influenza drugs, due to the lead-time required for production and rapid spread of the virus. To minimise the impact of pandemics it is imperative to maximise the availability of both vaccines and antivirals and to ensure that they are used optimally. This requires planning at both the international and national levels. The World Health Organization has, therefore, developed a staged plan for responding to a pandemic threat which is based principally on its surveillance program. It has also prepared guidelines to assist national agencies in their planning. However, there may be further options for increasing our preparedness which should also be considered.

Antiviral Agents↗

Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection.

Eight patients, convalescent from acute hepatitis, all negative for HBsAg, anti-HBc, anti-HA-IgM, anti-CMV and anti-EB, and all positive for non-A, non-B related antigen and/or antibody in at least one sample during the course of disease, were investigated. Their specific cell-mediated immunity was tested using the leukocyte migration inhibition test in presence of a previously described non-A, non-B related antigen. A control group consisted of ten individuals (two normal subjects, six patients recovering from acute hepatitis B and two with autoimmune chronic active hepatitis). Leukocyte migration was inhibited by the antigen in seven of the eight patients. The test was negative in all control subjects. It is thus demonstrated that after recovery, patients with non-A, non-B viral hepatitis develop a cellular immune response specific for purified non-A, non-B related antigen. The association between the described antigen and viral hepatitis non-A, non-B can now be established not only by immunoprecipitation, but also by a cellular test.

Adult↗

Anti-pre-S2 antibody response in subjects vaccinated against hepatitis B and in naturally immunized subjects.

Serum samples from individuals immunized with a pepsinized or non-pepsinized vaccine and from patients who had recovered from acute hepatitis B or who developed a chronic form of the disease, were analysed for the presence of antibody against the pre-S2 epitope of the hepatitis B virus. Anti-pre-S2 antibody was absent in all but one individual immunized with the pepsinized vaccine. Thirty-eight percent of the subjects who responded by anti-HBs production to the non-pepsinized preparation showed anti-pre-S2 antibody one year after complete vaccination. Among subjects who did not produce anti-HBs after immunization with this vaccine, 1 single individual produced anti-pre-S2 antibody. Anti-preS2 antibody was detectable after one year in 38% of the patients who recovered from acute hepatitis B, but in none of those with chronic hepatitis B. The kinetics of anti-pre-S2 antibody response to a booster injection was also analysed 1 month and 1 year after the 3rd injection and 1 month after the 4th injection of the non-pepsinized vaccine.

Acute Disease↗

Grouping of haemolytic streptococci by monoclonal antibodies: determinant specificity, cross-reactivity and affinity.

Streptococcal group polysaccharide (CHO), A-, A-variant-, B-, C-, D- and G-specific monoclonal antibodies were prepared by the hybridoma technique employing spleen cells of several inbred mouse strains which are either high or low responders to the group A-CHO. The isotypes of these reagents were restricted to the class mu and IgG subclasses gamma 3 and--in small numbers--gamma 1. Two distinct categories of antibodies were identified for all but group D specificity: those which agglutinate suspended bacteria but do not precipitate purified soluble antigen, and those which show both agglutinating and precipitating properties. The group D antibodies described here were only of the latter category. The reactions were inhibitable by haptens in as far as these were known. Cross-reactions were observed in group-A-specific antibodies with E and L polysaccharides. Most G-CHO-specific antibodies cross-reacted with B-CHO. Association constants determined by fluorescence quenching measurements were for binding of complete A and C polysaccharides in the range of 10(6) to greater than 10(8) M-1, and for hapten binding by A-, Av- and C-CHO-specific antibodies in the range of 10(3) to 10(4) M-1. These results support a model of steric arrangements of antigenic determinants on A-variant bacteria and solubilized antigen [42] and allow its extension to streptococcal groups A, B, C and G. This model explains the observed functional differences by postulating single, terminal determinants which interact with the prevailing non-precipitating antibodies and internal repeating determinants which react with precipitins, respectively. No significant differences were found in the reactivity patterns to these streptococcal group antigens between strains of mice in terms of their ability to respond with high or low serum antibody titres to group A-CHO. On the other hand, within high and low responder strains, different kinetics of the optimal timing of fusion after initiation of the secondary immune reaction by boosting was observed. Low responders were most efficiently used for fusion 1.5 days later than high-responder spleen cells. This feature is interpreted to indicate an earlier proliferation of B lymphocytes in high responders, due to either an improved responsiveness to T-lymphocyte help or a reduced reactivity with T suppressor cells in comparison to low-responder B lymphocytes.

Animals↗

Hepatitis C.

Hepatitis C has been identified as the most common cause of post-transfusion hepatitis worldwide, accounting for approximately 90% of this disease in Japan, the United States and Western Europe. Hepatitis C is a major global public health problem. New infections continue to occur, and the source of infection includes transfusion of blood or blood products from unscreened donors; transfusion of blood products that have not undergone viral inactivation; parenteral exposure to blood through use of contaminated and inadequately sterilized instruments and needles used in medical, dental and 'traditional' medicine; procedures such as hemodialysis; high risk sexual practices; household or sexual contacts of hepatitis C virus (HCV)-infected persons; and infants of HCV-infected mothers. In many countries, the relative contribution of the various sources of infection has not been defined with population-based epidemiological studies. Such studies are necessary to enable countries to prioritize their preventive measures and to make the most appropriate use of available resources. Given the substantial morbidity and mortality attributable to HCV-related chronic liver disease, each country, irrespective of economic status, should develop a plan of HCV-related public health activities for the prevention of new HCV infections and the treatment of established chronic infections.

Antiviral Agents↗